Role of Tranexamic Acid in Reducing Blood Loss During Caesarean Section

Prophylactic Tranexamic Acid for Reducing Intraoperative Blood Loss During Caesarean Section in Women at High risk of Postpartum Haemorrhage. A Double Blind Placebo Controlled Randomised Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202107872851363

Enrollment

200

Registered

2021-07-19

Start date

2021-07-24

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

Tranexamic acid

Normal Saline

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: All pregnant women at risk of PPH and booked for Caesarean section at ESUTH-Parklane.

Exclusion criteria

Exclusion criteria: Uterine rupture intra-uterine fetal death history of bleeding disorders history of thrombo-embolism significant antepartum haemorrhage known allergy to tranexamic acid

Design outcomes

Primary

Measure	Time frame
mean intra-operative blood loss during caesarean delivery and haematocrit change 48 hours postoperatively.	—

Secondary

Measure	Time frame
need for additional uterotonics, need for blood transfusion, need for other surgical intervention for PPH (such as B-lynch procedure, or hysterectomy), incidence of postpartum maternal anaemia and occurrence of adverse effects (nausea, vomiting, thrombo-embolism, coagulopathy, etc) during the surgery.	—

Countries

Nigeria

Contacts

Public ContactFrank Ezugwu

Professor

frankezugwu@yahoo.com08033979693

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026